Kurs & Likviditet
Kalender
2024-10-31 | Kvartalsrapport 2024-Q3 |
2024-08-16 | Kvartalsrapport 2024-Q2 |
2024-06-05 | Ordinarie utdelning NAVA 0.00 NOK |
2024-06-04 | Årsstämma 2024 |
2024-04-30 | Kvartalsrapport 2024-Q1 |
2024-02-15 | Bokslutskommuniké 2023 |
2023-11-01 | Kvartalsrapport 2023-Q3 |
2023-08-11 | Kvartalsrapport 2023-Q2 |
2023-06-02 | Ordinarie utdelning NAVA 0.00 NOK |
2023-06-01 | Årsstämma 2023 |
2023-05-11 | Kvartalsrapport 2023-Q1 |
2023-02-16 | Bokslutskommuniké 2022 |
2022-11-01 | Kvartalsrapport 2022-Q3 |
2022-08-12 | Kvartalsrapport 2022-Q2 |
2022-06-03 | Ordinarie utdelning NAVA 0.00 NOK |
2022-06-02 | Årsstämma 2022 |
2022-05-10 | Kvartalsrapport 2022-Q1 |
2022-02-17 | Bokslutskommuniké 2021 |
2021-11-04 | Kvartalsrapport 2021-Q3 |
2021-08-13 | Kvartalsrapport 2021-Q2 |
2021-06-04 | Ordinarie utdelning NAVA 0.00 NOK |
2021-06-03 | Årsstämma 2021 |
2021-05-11 | Kvartalsrapport 2021-Q1 |
2021-02-18 | Bokslutskommuniké 2020 |
2020-11-06 | Kvartalsrapport 2020-Q3 |
2020-08-20 | Kvartalsrapport 2020-Q2 |
2020-06-04 | Ordinarie utdelning NAVA 0.00 NOK |
2020-06-03 | Årsstämma 2020 |
2020-05-14 | Kvartalsrapport 2020-Q1 |
2020-03-11 | Extra Bolagsstämma 2020 |
2020-02-13 | Bokslutskommuniké 2019 |
2019-11-01 | Kvartalsrapport 2019-Q3 |
2019-08-23 | Kvartalsrapport 2019-Q2 |
2019-05-29 | Ordinarie utdelning NAVA 0.00 NOK |
2019-05-28 | Årsstämma 2019 |
2019-05-15 | Kvartalsrapport 2019-Q1 |
2019-02-14 | Bokslutskommuniké 2018 |
2018-12-20 | Extra Bolagsstämma 2018 |
2018-11-09 | Kvartalsrapport 2018-Q3 |
2018-08-24 | Kvartalsrapport 2018-Q2 |
2018-06-08 | Ordinarie utdelning NAVA 0.00 NOK |
2018-06-07 | Årsstämma 2018 |
2018-05-30 | Kvartalsrapport 2018-Q1 |
2018-02-15 | Bokslutskommuniké 2017 |
2017-11-10 | Kvartalsrapport 2017-Q3 |
2017-07-28 | Kvartalsrapport 2017-Q2 |
2017-06-07 | Ordinarie utdelning NAVA 0.00 NOK |
2017-06-06 | Årsstämma 2017 |
2017-05-10 | Kvartalsrapport 2017-Q1 |
2017-02-15 | Bokslutskommuniké 2016 |
2017-01-13 | Extra Bolagsstämma 2017 |
2016-11-11 | Kvartalsrapport 2016-Q3 |
2016-08-18 | Kvartalsrapport 2016-Q2 |
2016-06-21 | Ordinarie utdelning NAVA 0.00 NOK |
2016-06-20 | Årsstämma 2016 |
2016-05-11 | Kvartalsrapport 2016-Q1 |
2016-02-18 | Bokslutskommuniké 2015 |
2015-10-30 | Extra Bolagsstämma 2015 |
2015-10-30 | Kvartalsrapport 2015-Q3 |
2015-08-21 | Kvartalsrapport 2015-Q2 |
2015-06-09 | Ordinarie utdelning NAVA 0.00 NOK |
2015-06-08 | Årsstämma 2015 |
2015-04-28 | Kvartalsrapport 2015-Q1 |
2015-02-27 | Bokslutskommuniké 2014 |
2014-10-31 | Kvartalsrapport 2014-Q3 |
2014-08-22 | Kvartalsrapport 2014-Q2 |
2014-06-10 | Årsstämma 2014 |
2014-05-06 | Kvartalsrapport 2014-Q1 |
2014-02-27 | Bokslutskommuniké 2013 |
2013-11-01 | Kvartalsrapport 2013-Q3 |
2013-08-30 | Kvartalsrapport 2013-Q2 |
2013-06-13 | Kapitalmarknadsdag 2013 |
2013-05-23 | Årsstämma 2013 |
2013-04-25 | Kvartalsrapport 2013-Q1 |
2013-02-15 | Bokslutskommuniké 2012 |
2012-02-10 | Bokslutskommuniké 2011 |
2011-10-21 | Kvartalsrapport 2011-Q3 |
2011-08-25 | Kvartalsrapport 2011-Q2 |
2011-05-05 | Kvartalsrapport 2011-Q1 |
2011-04-14 | Årsstämma 2011 |
2011-02-04 | Bokslutskommuniké 2010 |
2010-10-28 | Kvartalsrapport 2010-Q3 |
2010-08-26 | Kvartalsrapport 2010-Q2 |
2010-05-05 | Kvartalsrapport 2010-Q1 |
2010-03-25 | Årsstämma 2010 |
2010-02-11 | Bokslutskommuniké 2009 |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
Oslo, 21 December 2023 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, today announces it has renewed its contract with Vitaflo International Limited (Vitaflo International), granting Navamedic the exclusive rights to market and distribute Vitaflo International's medical nutrition products across the Nordic region for an additional five years.
This agreement follows a longstanding partnership between Navamedic and Vitaflo International, dating back to 2005. Vitaflo International's medical nutrition products make up Navamedic's IEM (inborn error of metabolism) products and are part of the Hospital segment.
"We are thrilled to have renewed the contract with Vitaflo International, which underpins the strength of Navamedic's marketing and distribution channels in the Nordics. The medical nutrition product portfolio represents one of Navamedic's key product offerings to our customers in the Nordics, and we look forward to continuing our collaboration and partnership with Vitaflo International," commented Kathrine Gamborg Andreassen, CEO of Navamedic.
For further information, please contact:
Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, Navamedic
Mobile: +47917 62 842
E-mail: lars.hjarrand@navamedic.com
About Navamedic
Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit Navamedic.com.